Cancer IQ

This year marks “one of the worst financial years on record for hospitals,” according to Kaufman Hall. In this environment, the usual hospital revenue generation strategies won’t get off the ground. Going into 2023, hospital leaders will need to find ways to drive greater incremental revenue with the resources they already have.

You might be missing a significant portion of your patient population who would benefit from billable clinical services, like colonoscopies, breast MRIs and prophylactic surgeries. Read on to find out why preventive oncology that capture these patients – which is good for both patients and profit – should be on the top of every health system’s priority list.

Why Preventive Oncology is Good for Patients and Profit CancerIQ data shows 2 in 5 patients who undergo comprehensive cancer risk assessment and genetic testing require a change in medical management.

What most influences the underutilization of genetic testing and counseling? "The lack of an effective protocol to signal physicians" it's indicated. That's why we're working to arm every provider with the technology that incorporates comprehensive risk factors and cross references them with the most-up-to-date guidelines to increase uptake and adherence.

This urology practice's adoption of a guideline-based point-of-care risk assessment and testing protocol "approximately tripled the rate of patient compliance with recommended genetic testing: from 33.3% to 98.7%."

Genetic testing for prostate cancer increases after introduction of point-of-care program Some patients with prostate cancer have genetic mutations that may impact their treatment. A comprehensive, on-site genetic testing program, pioneered by urolog

A new skin cancer vaccine is delivering on the promises of personalized care pathways, and Dr. Stephen Hoge says "'this is a transformational moment for the field.' The key to the vaccine’s success is that it was tailored to each patient’s tumor, allowing each patient to mount a precise and targeted response to their cancer."

Personalized cancer vaccines may be on the way, but until they become widely available, health systems can start seeing the clinical and financial benefits of personalized care even sooner. The future of oncology focuses on moving upstream to intercept patients before a cancer diagnosis even occurs – enter precision prevention. Stay tuned for more from CancerIQ on how we're making this possible at scale.

Moderna's mRNA Skin Cancer Vaccine Shows Early Promise in a New Study The company reported encouraging results from a small study